Paroxysmal nocturnal hemoglobinuria (PNH) Highlights from ASH 2021
Jointly Provided by
Supported by an educational grant from Apellis.
Start date: March 14, 2022
End date: March 31, 2023
Estimated time to complete: 0.25 hours
NO LONGER AVAILABLE FOR CREDIT
Activity Description
At ASH 2021, new information and data were presented on paroxysmal nocturnal hemoglobinuria (PNH)—a rare, acquired blood disease characterized by hemolytic anemia, bone marrow failure, thrombosis, and fatigue.
This accredited CME activity highlights the latest information about PNH from ASH 2021 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients they may encounter with this rare condition.
Activity Faculty
Carlos De Castro, MD
Professor of Medicine
Hematologic Malignancies and Cellular Therapy
Duke Hematologic Malignancies Clinic
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in hematology, neurology, nephrology, immunology, gastroenterology, pulmonology, and cardiology. Other members of the care team may also participate.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage PNH and its clinical relevance
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
Faculty Educators
Dr. De Castro discloses the following relevant financial relationships:
- Advisory Board/Consultant: Alexion, Novartis, BioCryst
- Speakers’ Bureau: Apellis
- Other Relationships: BioCryst (DMC); Regeneron (IDMC)
Planners for this activity have no relevant financial relationships with any commercial interests.
This activity will review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.
Hardware/Software Requirements
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/
Contact
For any questions, please contact: CEServices@academycme.org
Copyright
© 2022. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
Paroxysmal nocturnal hemoglobinuria (PNH) Highlights from ASH 2021
References
Panse J et al. Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter. Abstract 2194.
Risitano A et al. Categorized Hematologic Response to Pegcetacoplan and Correlations with Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from Phase 1b, Phase 2a, and Phase 3 Trials. Abstract 1104.
Terriou L et al. Long-Term Survival Benefit of Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria: Data from the International PNH Registry. Abstract 2188.
Hoffman K et al. Evaluation of the Long-Term Safety and Efficacy of Pegcetacoplan Treatment for Paroxysmal Nocturnal Hemoglobinuria Patients: An Extension Study. Abstract 2175.
Wong R et al. Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study. Abstract 606.
Schrezenmeier H et al. Predictors for Improvement in Patient-Reported Outcomes: Post-Hoc Analysis of a Phase 3 Randomized, Open-Label Study of Eculizumab and Ravulizumab in Complement Inhibitor- Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Abstract 2196.
Yeh M et al. Changes in Hemoglobin Measures Observed in PNH Patients Treated with Both C5 Inhibitors Ravulizumab and Eculizumab: Real-World Evidence from a US-Based EMR Network. Abstract 1112.
Jang JH et al. 12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria. Abstract 2173.
Jang JH et al. Pozelimab, a Human Monoclonal Antibody Against Complement Factor C5, Provided Inhibition of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria. Abstract 1128.
Chavez EA et al. Total Oral Anticoagulation for Classic PNH As Primary Prophylaxis Strategy in a Complement Inhibitor Restricted Scenario: A Retrospective Analysis. Abstract 1118.
Cella D et al. Clinically Important Difference for the FACIT-Fatigue Scale in Paroxysmal Nocturnal Hemoglobinuria: A Derivation from International PNH Registry Patient Data. Abstract 1952.
Paroxysmal nocturnal hemoglobinuria (PNH) Highlights from ASH 2021 - references
Jointly Provided by
Supported by an educational grant from Apellis.
Start date: March 14, 2022
End date: March 31, 2023
Estimated time to complete: 0.25 hours
NO LONGER AVAILABLE FOR CREDIT
Activity Description
At ASH 2021, new information and data were presented on paroxysmal nocturnal hemoglobinuria (PNH)—a rare, acquired blood disease characterized by hemolytic anemia, bone marrow failure, thrombosis, and fatigue.
This accredited CME activity highlights the latest information about PNH from ASH 2021 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients they may encounter with this rare condition.
Activity Faculty
Carlos De Castro, MD
Professor of Medicine
Hematologic Malignancies and Cellular Therapy
Duke Hematologic Malignancies Clinic
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in hematology, neurology, nephrology, immunology, gastroenterology, pulmonology, and cardiology. Other members of the care team may also participate.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage PNH and its clinical relevance
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
Faculty Educators
Dr. De Castro discloses the following relevant financial relationships:
- Advisory Board/Consultant: Alexion, Novartis, BioCryst
- Speakers’ Bureau: Apellis
- Other Relationships: BioCryst (DMC); Regeneron (IDMC)
Planners for this activity have no relevant financial relationships with any commercial interests.
This activity will review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.
Hardware/Software Requirements
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/
Contact
For any questions, please contact: CEServices@academycme.org
Copyright
© 2022. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
Paroxysmal nocturnal hemoglobinuria (PNH) Highlights from ASH 2021
Slides
